PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
May 1, 2006, 00:00
10.1016/S1098-3015(10)64387-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)64387-2/fulltext
Title :
PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64387-2&doi=10.1016/S1098-3015(10)64387-2
First page :
Section Title :
Open access? :
No
Section Order :
288